METASTATIC CASTRATION-RESISTANT PROSTATE NEOPLASMS
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE NEOPLASMS trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New T-Cell therapy aims to fight Hard-to-Treat prostate cancer
Disease control Recruiting nowThis phase 3 study tests a drug called pasritamig, which helps the body's immune T-cells attack prostate cancer cells. The trial includes 663 men with metastatic castration-resistant prostate cancer, a stage where standard hormone therapy no longer works. Participants receive eit…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for advanced prostate cancer? early trial tests targeted combo therapy
Disease control Recruiting nowThis early-phase study is testing a new drug called pasritamig (JNJ-78278343) combined with other treatments for men with metastatic prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose. About 300 participants will be …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE NEOPLASMS
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC